Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer-Reference-Cited by-同舟云学术

Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer

Published:2024-04-15 Issue:3 Volume:57 Page:177-184
ISSN:1860-1480
Container-title:Medical Molecular Morphology
language:en
Short-container-title:Med Mol Morphol

Author:

Narusawa Eriko^ORCID,Kurozumi Sasagu,Katayama Ayaka,Koibuchi Yukio,Ogawa Akira,Takata Daisuke,Tokuda Shoko,Obayashi Sayaka,Oyama Tetsunari,Horiguchi Jun,Shirabe Ken,Fujii Takaaki

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00795-024-00386-z.pdf

Reference37 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

2. Kurozumi S, Katayama A, Shirabe K, Horiguchi J, Rakha EA (2021) Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer. Oncotarget 12:2302–2304

3. Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM (2019) OlympiAD final overall survival and tolerability results: nternal versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30:558–566

4. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, KEYNOTE-355 Investigators (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a nternaliz, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817–1828

5. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O’Shaughnessy J, KEYNOTE-522 Investigators (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821